

Taxol (paclitaxel)

Effective Date: 10/22/13

Date Developed: 09/3/13 by Albert Reeves MD

Last Approval Date: 1/26/16, 1/24/17, 1/23/18,
1/22/19, 2/18/20

Paclitaxel is a plant-derived mitotic-inhibiting antineoplastic agent used in cancer chemotherapy.

Pre-Authorization Criteria:

VCHCP will authorize Taxol for the following: ovarian carcinoma; metastatic breast cancer; nonsmall cell lung cancer; AIDS-related Kaposi's sarcoma

Adult Dosing (should be prescribed by an Oncologist):

Ovarian carcinoma:

I.V.: 135-175 mg/m² over 3 hours every 3 weeks **or**

135 mg/m² over 24 hours every 3 weeks **or**

50-80 mg/m² over 1-3 hours weekly **or**

1.4-4 mg/m²/day continuous infusion for 14 days every 4 weeks

Intraperitoneal (unlabeled route): 60 mg/m² on day 8 of a 21-day treatment cycle for 6 cycles, in combination with I.V. paclitaxel and intraperitoneal cisplatin. **Note:** Administration of intraperitoneal paclitaxel should include the standard paclitaxel premedication regimen.

Metastatic breast cancer: I.V.: 175-250 mg/m² over 3 hours every 3 weeks **or**

50-80 mg/m² weekly **or**

1.4-4 mg/m²/day continuous infusion for 14 days every 4 weeks

Nonsmall cell lung carcinoma: I.V.: 135 mg/m² over 24 hours every 3 weeks

AIDS-related Kaposi's sarcoma: I.V.: 135 mg/m² over 3 hours every 3 weeks

or 100 mg/m² over 3 hours every 2 weeks

Note: adjustments should be made for hepatic impairment

PRECAUTIONS: bone marrow suppression; hypersensitivity reaction [U.S. Boxed warning]; peripheral neuropathy; infusion-associated hypotension; elderly (increased risk of toxicity)

DRUG INTERACTIONS: There are several potential drug interactions (e.g. other antineoplastic agents, clozapine, CYP2C8 AND CYP3A4 effects, numerous herbs, etc). Refer to product information for complete listing.

REFERENCES

1. Armstrong DK, Bundy B, Wenzel L, et al, "Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer," *N Engl J Med*, 2006, 354(1):34-43. [PubMed 16394300]
2. Aronoff GR, Bennett WM, Berns JS, et al, *Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children*, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 101.
3. Baker AF and Dorr RT, "Drug Interactions With the Taxanes: Clinical Implications," *Cancer Treat Rev*, 2001, 27(4):221-33. [PubMed 11545542]
4. Berveiller P, Vinot C, Mir O, et al, "Comparative Transplacental Transfer of Taxanes Using the Human Perfused Cotyledon Placental Model," *Am J Obstet Gynecol*, 2012, 207(6):514.e1-514.e7. [PubMed 23174392]
5. Floyd JD, Nguyen DT, Lobins RL, et al, "Cardiotoxicity of Cancer Therapy," *J Clin Oncol*, 2005, 23(30):7685- 96. [PubMed 16234530]
6. Griffin SJ, Milla M, Baker TE, et al, "Transfer of Carboplatin and Paclitaxel into Breast Milk," *J Hum Lact*, 2012, 28(4):457-9. [PubMed 23087196]
7. Griggs JJ, Mangu PB, Anderson H, et al, "Appropriate Chemotherapy Dosing For Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline," *J Clin Oncol*, 2012, 30(13):1553-61. [PubMed 22473167]
8. Hanioka N, Matsumoto K, Saito Y, et al, "Functional Characterization of CYP2C8.13 and CYP2C8.14: Catalytic Activities Toward Paclitaxel," *Basic Clin Pharmacol Toxicol*, 2010, 107(1):565-9. [PubMed 20148860]
9. Hesketh PJ, Kris MG, Grunberg SM, et al, "Proposal for Classifying the Acute Emetogenicity of Cancer Chemotherapy," *J Clin Oncol*, 1997, 15(1):103-9. [PubMed 8996130]
10. Holmes FA, "Paclitaxel Combination Therapy in the Treatment of Metastatic Breast Cancer: A Review," *Semin Oncol*, 1996, 23(5 Suppl 11):46-56.
11. Janus N, Thariat J, Boulanger H, et al, "Proposal for Dosage Adjustment and Timing of Chemotherapy in Hemodialyzed Patients," *Ann Oncol*, 2010, 21(7):1395-403. [PubMed 20118214]
12. Longnecker SM, Donehower RC, Cates AE, et al, "High-Performance Liquid Chromatographic Assay for Taxol in Human Plasma and Urine and Pharmacokinetics in a Phase I Trial," *Cancer Treat Rep*, 1987, 71(1):53-9. [PubMed 2878719]
13. Mekhail TM and Markman M, "Paclitaxel in Cancer Therapy," *Expert Opin Pharmacother*, 2002, 3(6):755-66. [PubMed 12036415]
14. Miller K, Wang M, Gralow J, et al, "Paclitaxel Plus Bevacizumab Versus Paclitaxel Alone for Metastatic Breast Cancer," *N Engl J Med*, 2007, 357(26):2666-76. [PubMed 18160686]
15. Morgan C, Tillett T, Braybrooke J, et al, "Management of Uncommon Chemotherapy-Induced Emergencies," *Lancet Oncol*, 2011, 12(8):806-14. [PubMed 21276754]
16. National Institute for Occupational Safety and Health (NIOSH), "NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012." Available at <http://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf>. Accessed January 21, 2013.
17. Pérez Fidalgo JA, García Fabregat L, Cervantes A, et al, "Management of Chemotherapy Extravasation: ESMO-EONS Clinical Practice Guidelines," *Ann Oncol*, 2012, 23(Suppl 7):167-73. [PubMed 22997449]
18. Rowinsky EK and Donehower RC, "Paclitaxel (Taxol)," *N Engl J Med*, 1995, 332(15):1004-14. [PubMed 7885406]
19. Rowinsky EK, "The Taxanes: Dosing and Scheduling Considerations," *Oncology*, 1997, 11(3 Suppl 2):7-19.
20. Seetalarom K, Kudelka AP, Verschraegen CF, et al, "Taxanes in Ovarian Cancer Treatment," *Curr Opin Obstet Gynecol*, 1997, 9(1):14-20. [PubMed 9090476]
21. Sonnichsen DS and Relling MV, "Clinical Pharmacokinetics of Paclitaxel," *Clin Pharmacokinet*, 1994, 27(4):256-69. [PubMed 7834963]
22. Spencer CM and Faulds D, "Paclitaxel. A Review of Its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Potential in the Treatment of Cancer," *Drugs*, 1994, 48(5):794-847. [PubMed 7530632]

Revision History:

Date Approved by P&T Committee: 10/22/13

Date Reviewed/No Updates: 1/28/14 by C. Sanders MD

Date Approved by P&T Committee: 1/28/14

Date Reviewed/No Updates: 1/13/15 by C. Sanders, MD
 Date Approved by P&T Committee: 1/27/15
 Date Reviewed/No Updates: 1/26/16 by C. Sanders, MD; R. Sterling, MD
 Date Approved by P&T Committee: 1/26/16
 Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD
 Date Approved by P&T Committee: 1/24/17
 Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD; R. Sterling, MD
 Date Approved by P&T Committee: 1/23/18
 Date Reviewed/No Updates: 1/22/19 by C. Sanders, MD; R. Sterling, MD
 Date Approved by P&T Committee: 1/22/19
 Date Reviewed/No Updates: 2/18/20 by H. Taekman, MD; R. Sterling, MD
 Date Approved by P&T Committee: 2/18/20

Revision Date	Content Revised (Yes/No)	Contributors	Review/Revision Notes
1/24/17	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/23/18	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/22/19	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
2/18/20	No	Howard Taekman, MD; Robert Sterling, MD	Annual review